Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.46 |
| ▸ | JAK1 | P23458 | 6/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 5/20 | 0.42 |
| ▸ | JAK3 | P52333 | 4/20 | 0.42 |
| ▸ | IGF1R | P08069 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28722982 | 1.00 | JAK2 (0.46) | JAK2JAK1GRIN2BSMN1; SMN2NPC1 | |
| SCHEMBL14654246 | 0.96 | JAK2 (0.47) | JAK2JAK1GRIN2BSMN1; SMN2NPC1 | |
| SCHEMBL21050956 | 0.93 | JAK2 (0.42) | JAK2JAK1GRIN2BSMN1; SMN2NPC1 | |
| SCHEMBL30449939 | 0.91 | IGF1R (0.49) | JAK2JAK1TYK2JAK3IGF1R | |
| SCHEMBL12442146 | 0.89 | JAK2 (0.47) | JAK2JAK1GRIN2BSMN1; SMN2NPC1 | |
| SCHEMBL21050808 | 0.89 | IGF1R (0.49) | JAK2JAK1SMN1; SMN2CYP2C19IGF1R | |
| SCHEMBL26359420 | 0.89 | GRIN2B (0.46) | JAK2JAK1GRIN2BSMN1; SMN2NPC1 | |
| SCHEMBL28724598 | 0.89 | IGF1R (0.49) | JAK2JAK1SMN1; SMN2CYP2C19IGF1R | |
| SCHEMBL14647465 | 0.86 | JAK2 (0.47) | JAK2JAK1GRIN2BSMN1; SMN2NPC1 | |
| SCHEMBL15929297 | 0.85 | IGF1R (0.51) | JAK2JAK1TYK2JAK3IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109896-A1 | FGFR KINASE INHIBITOR AND USE THEREOF | YA THERAPEUTICS INC (CN) | 2024-04-04 | — | — | US | disclosed |
| WO-2022166469-A1 | FGFR KINASE INHIBITOR AND USE THEREOF | 药雅科技(上海)有限公司 | 2022-08-11 | — | — | WO | disclosed |
| CN-109715626-B | Heterocyclic compounds as FGFR inhibitors | 广州诺诚健华医药科技有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-10752631-B2 | Heterocyclic compounds as FGFR inhibitors | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2020-08-25 | — | — | US | disclosed |
| EP-3498706-A1 | HETEROCYCLIC COMPOUND AS FGFR INHIBITOR | Guangzhou InnoCare Pharma Tech Co., Ltd. (CN) | 2019-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109896-A1 | FGFR KINASE INHIBITOR AND USE THEREOF | FGFR1, FGFR2, FGFR3 | JAK2 11/4885JAK1 17/4885GRIN2B 1214/4885 |
| US-10752631-B2 | Heterocyclic compounds as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | JAK2 72/4885JAK1 108/4885GRIN2B 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.